Alphamab Oncology (FRA:3NK)

Germany flag Germany · Delayed Price · Currency is EUR
1.190
-0.020 (-1.65%)
Last updated: Apr 24, 2026, 9:05 AM CET
Market Cap1.21B +29.8%
Revenue (ttm)68.95M -11.5%
Net Income-13.87M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume81
Open1.190
Previous Close1.210
Day's Range1.190 - 1.190
52-Week Range0.645 - 1.680
Betan/a
RSI62.40
Earnings DateMar 25, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 498
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3NK

Financial Performance

Financial numbers in CNY Financial Statements

News

Alphamab Oncology's JSKN033 Cleared For Phase 2 Cervical Cancer Trial By Chinese Regulatory Agency

(RTTNews) - Alphamab Oncology's (9966.HK) Investigational New Drug application for a phase 2 clinical trial of JSKN033 as first-line treatment of advanced cervical cancer has been accepted by the Cent...

4 months ago - Nasdaq